ReviewDiabetes care2018
Hypogonadotropic Hypogonadism in Men With Diabesity.
Review in Diabetes care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 150 citations in OpenAlex.
- Acute Effects of Glucagon on Reproductive Hormone Secretion in Healthy Men.The Journal of clinical endocrinology and metabolism · 2020Trial
- Effects of Glucagon-like Peptide-1 on the Reproductive Axis in Healthy Men.The Journal of clinical endocrinology and metabolism · 2020Trial
- Effects of Incretin-Based Therapies on Testosterone Levels and Incretin Response in Men with Hypogonadism: A Systematic Literature Review Following PRISMA 2020 Guidelines.Pharmaceuticals (Basel, Switzerland) · 2026Review
- High Uric Acid Promotes Stem Leydig Cell Senescence by CCDC90B Mediates Mitochondrial Quality Control Imbalance.Cell proliferation · 2026Article
- Low Testosterone in Men With Type 2 Diabetes: The Role of Estrogen Excess and Aromatase Activity.Clinical endocrinology · 2026Article
- Hypogonadotropic Hypogonadism in a Central Obesity Patient with 46, XY, t(1; 10)(q42; q24).JBRA assisted reproduction · 2025Article
- Prevalence of Hypogonadism Among Males with Type 2 Diabetes Mellitus in a Malaysian Tertiary Hospital: A Cross-Sectional Study.Journal of the ASEAN Federation of Endocrine Societies · 2025Article
- Distinct patterns of hypogonadism in a cross-sectional study of Malaysian men with type 2 diabetes mellitus: The role of insulin resistance, visceral adiposity, and aging.Journal of diabetes investigation · 2025Article
- Sex Steroids in COVID-19 Patients with Hypertension: An Exploratory Study.International journal of molecular sciences · 2025Article
- Association of age and insulin resistance with sex hormone-binding globulin levels in healthy men.Archives of endocrinology and metabolism · 2025Article
- One Size Does Not Fit All: The Need for Sex-Specific Precision Medicine in Diabetes Technology.Journal of diabetes science and technology · 2025Article
- FREQUENCY AND CORRELATES OF HYPOGONADISM AMONG A COHORT OF NIGERIAN MEN WITH TYPE 2 DIABETES MELLITUS.Annals of Ibadan postgraduate medicine · 2025Article
- Validity between dual-energy x-ray absorptiometry and bioelectrical impedance for segmental fat analysis and a novel low-cost model developed using anthropometry in young adults.Journal of translational medicine · 2025Article
- The role of adipose tissue in puberty and reproductive health.Frontiers in endocrinology · 2025Review
- Editorial: Male hypogonadism: need for reclassification?Frontiers in endocrinology · 2024Article
- Article
- Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.Frontiers in cell and developmental biology · 2024Review
- Beyond the Metabolic Syndrome: Non-Obvious Complications of Obesity in Children.Children (Basel, Switzerland) · 2023Review
- Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice.Biomedicines · 2023Article
- Update on acquired hypogonadism in men living with HIV: pathogenesis, clinic, and treatment.Frontiers in endocrinology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
One-third of men with obesity or type 2 diabetes have subnormal free testosterone concentrations. The lower free testosterone concentrations are observed in obese men at all ages, including adolescents at completion of puberty. The gonadotropin concentrations in these males are inappropriately normal; thus, these patients have hypogonadotropic hypogonadism (HH). The causative mechanism of diabesity-induced HH is yet to be defined but is likely multifactorial. Decreased insulin and leptin signaling in the central nervous system are probably significant contributors. Contrary to popular belief, estrogen concentrations are lower in men with HH. Men with diabesity and HH have more fat mass and are more insulin resistant than eugonadal men. In addition, they have a high prevalence of anemia and higher mortality rates than eugonadal men. Testosterone replacement therapy results in a loss of fat mass, gain in lean mass, and increase in insulin sensitivity in men with diabesity and HH. This is accompanied by an increase in insulin-signaling genes in adipose tissue and a reduction in inflammatory mediators that interfere with insulin signaling. There is also an improvement in sexual symptoms, anemia, LDL cholesterol, and lipoprotein (a). However, testosterone therapy does not consistently affect HbA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.